Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTIYVQP)

• DTT Name: Polo-like kinase 1 (PLK1) DTT Info
• Gene Name: PLK1

Molecule-Related Drug & Molecule List

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rigosertib	DMOSTXF	Myelodysplastic syndrome	2A37	Phase 3	[1]
Volasertib	DMOFH1M	Acute myeloid leukaemia	2A60	Phase 3	[2]
BI 2536	DMJSADP	Acute myeloid leukaemia	2A60	Phase 2	[3]
PCM-075	DMYFRTB	Acute myeloid leukaemia	2A60	Phase 2	[4]
CYC140	DMC6PKJ	Acute myeloid leukaemia	2A60	Phase 1	[5]
GSK461364	DM0P729	Non-hodgkin lymphoma	2B33.5	Phase 1	[3]
MK-1496	DME1ZAH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
TAK-960	DMN4OGH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]

2 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dihydropyrido pyrazinone compound 2	DMOTG2Y	N. A.	N. A.	Patented	[8]
Dihydropyrido pyrazinone compound 3	DM3PEUN	N. A.	N. A.	Patented	[8]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HMN-214	DMH4ANG	Pancreatic cancer	2C10	Discontinued in Phase 1	[3]

3 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CYC-800	DMA1MK5	Solid tumour/cancer	2A00-2F9Z	Preclinical	[3]
DAP-81	DMUWRIF	Solid tumour/cancer	2A00-2F9Z	Preclinical	[3]
ZK-thiazolidinone	DMNG84V	Solid tumour/cancer	2A00-2F9Z	Preclinical	[3]

8 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CHR-4125	DMXKU73	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
GSK579289A	DMJXHU8	Discovery agent	N.A.	Investigative	[9]
GW853606	DMITKX8	Discovery agent	N.A.	Investigative	[10]
LC-445	DMYONVF	Solid tumour/cancer	2A00-2F9Z	Investigative	[3]
MLN-0905	DMTU0IG	Lymphoma	2A80-2A86	Investigative	[2]
NMS-1	DMX4ZGL	Solid tumour/cancer	2A00-2F9Z	Investigative	[3]
PMID19097784C2	DMH70UC	Discovery agent	N.A.	Investigative	[10]
Ro5203280	DM42UK5	Nasopharyngeal carcinoma	2B6B	Investigative	[11]

References

• [1] Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
• [3] Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of Cyclacel Pharmaceuticals.
• [6] J Clin Oncol 29: 2011 (suppl; abstr 3012).
• [7] TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther. 2012 Mar;11(3):700-9.
• [8] BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
• [9] Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1694-7.
• [10] Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21.
• [11] Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.